Ligand Pharmaceuticals Incorporated (Ligand) operates as a biopharmaceutical company.
The company's primary business is investing in and structuring royalty interests in mid- to late-stage development and commercial biopharmaceutical products, allow…
Analysis
Hope premium
Ligand Pharmaceuticals Incorporated carries what we call a hope premium: an average business trading at an ambitious price.
The price is expensive. You pay 27.3× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone. At today's price, the market is assuming roughly 10% yearly growth; analysts expect 18%. The price, in other words, assumes less than the experts do.
The trajectory is solid and the balance sheet is adequate. The company scores 18/20 on our value-creation score: strong value creator. Analysts lean positive.
What to watch: Some accounting patterns deserve a closer look. Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Mar 202696
91
2026
All-time high
96
Mar 2026
All-time low
91
Jun 2026
Average rank
94
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
23
—
—
—
Price/Earnings
19
—
—
—
Price/Book
37
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
6
—
—
—
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.